These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11496466)

  • 1. Funding arrangements for pharmaceuticals: can economic evaluation promote efficiency?
    Viney R
    Aust Health Rev; 2001; 24(2):21-4. PubMed ID: 11496466
    [No Abstract]   [Full Text] [Related]  

  • 2. And on the cover of the guide were two words in red--don't panic.
    Harvey R
    Aust Health Rev; 2001; 24(2):15-20. PubMed ID: 11496457
    [No Abstract]   [Full Text] [Related]  

  • 3. Australia's pharmaceutical benefits system: flawed but improving, and better than anywhere else.
    Dalton A
    Aust Health Rev; 2001; 24(2):7-14. PubMed ID: 11496474
    [No Abstract]   [Full Text] [Related]  

  • 4. Easy ride for drug industry.
    McBane M
    Health Aff (Millwood); 2003; 22(4):259-60. PubMed ID: 12889775
    [No Abstract]   [Full Text] [Related]  

  • 5. The pharmaceutical situation in the Philippines.
    Hartigan-Go K
    Aust Health Rev; 2001; 24(2):25-31. PubMed ID: 11496467
    [No Abstract]   [Full Text] [Related]  

  • 6. Basing prescription drug payment on economic analysis: the case of Australia.
    Drummond MF
    Health Aff (Millwood); 1992; 11(4):191-6. PubMed ID: 1483639
    [No Abstract]   [Full Text] [Related]  

  • 7. Implications of the Australian guidelines for the United States.
    Freund DA; Evans D; Henry D; Dittus R
    Health Aff (Millwood); 1992; 11(4):202-6. PubMed ID: 1483641
    [No Abstract]   [Full Text] [Related]  

  • 8. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The subsidy of pharmaceuticals in Australia: processes and challenges.
    Sansom L
    Aust Health Rev; 2004 Nov; 28(2):194-205. PubMed ID: 15527399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry.
    Bloor K; Maynard A; Freemantle N
    BMJ; 1996 Jul; 313(7048):33-5. PubMed ID: 8664771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Issues in mandatory economic assessment of pharmaceuticals.
    Bloom BS
    Health Aff (Millwood); 1992; 11(4):197-201. PubMed ID: 1483640
    [No Abstract]   [Full Text] [Related]  

  • 12. The politics of health.
    Blewett N
    Aust Health Rev; 2000; 23(2):10-9. PubMed ID: 11010563
    [No Abstract]   [Full Text] [Related]  

  • 13. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A catastrophe in health care.
    Cassels A
    Can Nurse; 2009 Nov; 105(9):52. PubMed ID: 19998693
    [No Abstract]   [Full Text] [Related]  

  • 15. Implications for managed care organizations of the Merck and Medco consent.
    Pollard MR; Tilson HH
    Med Interface; 1996 Mar; 9(3):60-2. PubMed ID: 10184511
    [No Abstract]   [Full Text] [Related]  

  • 16. When success sours: PBMs under scrutiny.
    Carroll J
    Manag Care; 2002 Sep; 11(9):20-6. PubMed ID: 12369344
    [No Abstract]   [Full Text] [Related]  

  • 17. Eliminating innovation: how price controls limit access.
    Ingram J
    J Leg Med; 2011 Jan; 32(1):115-28. PubMed ID: 21391059
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance.
    Yang BM; Bae EY; Kim J
    Health Aff (Millwood); 2008; 27(1):179-87. PubMed ID: 18180493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PBS reform - a missed opportunity?
    de Boer R
    Aust Health Rev; 2009 May; 33(2):176-85. PubMed ID: 19563306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter from the Commissioner's Office at the US FDA.
    Vernon JA
    Pharmacoeconomics; 2007; 25(4):267-8. PubMed ID: 17402801
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.